{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:17Z","timestamp":1793146637500,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004794","name":"CNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008222","name":"University of Montpellier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008222","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.antiviral.2019.02.014","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T12:02:36Z","timestamp":1551268956000},"page":"162-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Insight into the mechanism of action of EP-39, a bevirimat derivative that inhibits HIV-1 maturation"],"prefix":"10.1016","volume":"164","author":[{"given":"Aymeric","family":"Neyret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Cransac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Briant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8484-1381","authenticated-orcid":false,"given":"Pascale","family":"Coric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Turcaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0777-4992","authenticated-orcid":false,"given":"Philippe","family":"Laug\u00e2a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-8307","authenticated-orcid":false,"given":"Serge","family":"Bouaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1528-9607","authenticated-orcid":false,"given":"Nathalie","family":"Chazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.02.014_bib1","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1128\/JVI.72.3.2072-2078.1998","article-title":"A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly","volume":"72","author":"Accola","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib2","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1128\/JVI.01369-06","article-title":"In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat)","volume":"80","author":"Adamson","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1742-4690-7-36","article-title":"Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat","volume":"7","author":"Adamson","year":"2010","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.02.014_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4236\/wja.2011.14017","article-title":"HIV-1 assembly, release and maturation","volume":"1","author":"Briant","year":"2011","journal-title":"World J. AIDS"},{"key":"10.1016\/j.antiviral.2019.02.014_bib5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jmb.2011.04.021","article-title":"The molecular architecture of HIV","volume":"410","author":"Briggs","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1742-4690-5-57","article-title":"VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability","volume":"5","author":"Brun","year":"2008","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.02.014_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.virol.2010.01.028","article-title":"The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation","volume":"400","author":"Checkley","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.02.014_bib8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/bioinformatics\/btr013","article-title":"The CCPN Metabolomics Project: a fast protocol for metabolite identification by 2D-NMR","volume":"27","author":"Chignola","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.antiviral.2019.02.014_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejmech.2013.01.013","article-title":"Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site","volume":"62","author":"Coric","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.02.014_bib10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/135965350701200807","article-title":"The 3-O-(3\u2019,3\u2019-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells","volume":"12","author":"DaFonseca","year":"2007","journal-title":"Antivir. Ther. (Lond.)"},{"key":"10.1016\/j.antiviral.2019.02.014_bib11","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1021\/jm3016969","article-title":"New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1","volume":"56","author":"Dang","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.02.014_bib12","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1128\/JVI.00006-11","article-title":"On the role of the SP1 domain in HIV-1 particle assembly: a molecular switch?","volume":"85","author":"Datta","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0959-440X(02)00344-5","article-title":"Rotamer libraries in the 21st century","volume":"12","author":"Dunbrack","year":"2002","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrmicro3490","article-title":"HIV-1 assembly, release and maturation","volume":"13","author":"Freed","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/np50104a008","article-title":"Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzygium claviflorum, and the anti-HIV activity of structurally related triterpenoids","volume":"57","author":"Fujioka","year":"1994","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.antiviral.2019.02.014_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/978-1-4614-0980-9_20","article-title":"Assembly and architecture of HIV","volume":"726","author":"Ganser-Pornillos","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1742-4690-10-157","article-title":"HIV-1-associated PKA acts as a cofactor for genome reverse transcription","volume":"10","author":"Giroud","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.02.014_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/emboj\/19.1.103","article-title":"A conformational switch controlling HIV-1 morphogenesis","volume":"19","author":"Gross","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2019.02.014_bib19","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1128\/JVI.79.3.1803-1812.2005","article-title":"Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag","volume":"79","author":"Guo","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib20","series-title":"Investigation of Exchange Processes by Two\u2010dimensional NMR Spectroscopy","author":"Jeener","year":"1979"},{"key":"10.1016\/j.antiviral.2019.02.014_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/prot.340230312","article-title":"Successful protein fold recognition by optimal sequence threading validated by rigorous blind testing","volume":"23","author":"Jones","year":"1995","journal-title":"Proteins"},{"key":"10.1016\/j.antiviral.2019.02.014_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/AAC.45.4.1225-1230.2001","article-title":"Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation","volume":"45","author":"Kanamoto","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.02.014_bib24","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1021\/jm950922q","article-title":"Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents","volume":"39","author":"Kashiwada","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.02.014_bib25","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1128\/JVI.01926-10","article-title":"HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice","volume":"85","author":"Keller","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.virol.2015.03.021","article-title":"Retroviral proteases and their roles in virion maturation","volume":"479\u2013480","author":"Konvalinka","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.02.014_bib27","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1128\/jvi.69.6.3407-3419.1995","article-title":"The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity","volume":"69","author":"Kr\u00e4usslich","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib28","doi-asserted-by":"crossref","first-page":"13555","DOI":"10.1073\/pnas.2234683100","article-title":"PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing","volume":"100","author":"Li","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.02.014_bib29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1742-4690-10-126","article-title":"Functional conservation of HIV-1 Gag: implications for rational drug design","volume":"10","author":"Li","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.02.014_bib30","doi-asserted-by":"crossref","first-page":"11729","DOI":"10.1128\/JVI.76.22.11729-11737.2002","article-title":"Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag","volume":"76","author":"Liang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib31","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.bmc.2016.03.001","article-title":"C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors","volume":"24","author":"Liu","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.02.014_bib32","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1128\/AAC.01435-10","article-title":"A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.02.014_bib33","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AAC.01784-09","article-title":"Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat","volume":"54","author":"Margot","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.02.014_bib34","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.1128\/JVI.78.18.9675-9688.2004","article-title":"The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release","volume":"78","author":"Melamed","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1110\/ps.041087605","article-title":"Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging","volume":"14","author":"Morellet","year":"2005","journal-title":"Protein Sci."},{"issue":"7","key":"10.1016\/j.antiviral.2019.02.014_bib101","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1128\/AAC.02560-15","article-title":"Identification and characterization of BMS-955176, a second-generation HIV-1 maturation inhibitor with improved potency, antiviral spectrum, and gag polymorphic coverage","volume":"60","author":"Nowicka-Sans","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.antiviral.2019.02.014_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1742-4690-8-101","article-title":"The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles","volume":"8","author":"Nguyen","year":"2011","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.02.014_bib37","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/jvi.68.12.8017-8027.1994","article-title":"The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions","volume":"68","author":"Pettit","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib38","doi-asserted-by":"crossref","first-page":"8128","DOI":"10.1021\/jm301040s","article-title":"Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors","volume":"55","author":"Qian","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.02.014_bib39","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1021\/jm901782m","article-title":"Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors","volume":"53","author":"Qian","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.02.014_bib40","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsmedchemlett.6b00010","article-title":"Discovery of BMS-955176, a second generation HIV-1 maturation inhibitor with broad spectrum antiviral activity","volume":"7","author":"Regueiro-Ren","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2019.02.014_bib41","first-page":"79","article-title":"Maturation inhibitors as new antiretroviral agents","volume":"13","author":"Richards","year":"2008","journal-title":"J. HIV Ther."},{"key":"10.1016\/j.antiviral.2019.02.014_bib42","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1128\/jvi.71.7.4892-4903.1997","article-title":"Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag\/protease and particle formation","volume":"71","author":"Schneider","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib43","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1126\/science.aaf9620","article-title":"An atomic model of HIV-1 capsid-SP1 reveals structures regulating assembly and maturation","volume":"353","author":"Schur","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.02.014_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/QAD.0b013e328335ce07","article-title":"High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor","volume":"24","author":"Secl\u00e9n","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.02.014_bib45","doi-asserted-by":"crossref","first-page":"e1251","DOI":"10.1371\/journal.pone.0001251","article-title":"Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy\/Liv mice","volume":"2","author":"Stoddart","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.02.014_bib46","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006924","article-title":"HIV-1 assembly, budding, and maturation","volume":"2","author":"Sundquist","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.antiviral.2019.02.014_bib47","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.bmcl.2016.03.019","article-title":"Inhibitors of HIV-1 maturation: development of structure-activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids","volume":"26","author":"Swidorski","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2019.02.014_bib48","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1128\/JVI.02698-15","article-title":"Mutations of conserved residues in the major Homology region arrest assembling HIV-1 gag as a membrane-targeted intermediate containing genomic RNA and cellular proteins","volume":"90","author":"Tanaka","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1874104501408010023","article-title":"Synthesis and biological evaluation of macrocyclized betulin derivatives as a novel class of anti-HIV-1 maturation inhibitors","volume":"8","author":"Tang","year":"2014","journal-title":"Open Med. Chem. J."},{"key":"10.1016\/j.antiviral.2019.02.014_bib50","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.bmcl.2017.04.042","article-title":"Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms","volume":"27","author":"Tang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2019.02.014_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virol.2018.05.024","article-title":"Maturation inhibitors facilitate virus assembly and release of HIV-1 capsid P224 mutant","volume":"521","author":"Timilsina","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.02.014_bib52","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1128\/AAC.02121-15","article-title":"Alkyl amine bevirimat derivatives are potent and broadly active HIV-1 maturation inhibitors","volume":"60","author":"Urano","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.02.014_bib53","article-title":"Resistance to second-generation HIV-1 maturation inhibitors","author":"Urano","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib54","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.01650-08","article-title":"Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1","volume":"53","author":"Van Baelen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.02.014_bib55","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1128\/JVI.77.9.5439-5450.2003","article-title":"Functional surfaces of the human immunodeficiency virus type 1 capsid protein","volume":"77","author":"von Schwedler","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib56","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.17063","article-title":"Crystal structure of an HIV assembly and maturation switch","volume":"5","author":"Wagner","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.antiviral.2019.02.014_bib57","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/aid.2011.0230","article-title":"HIV type 1 Gag as a target for antiviral therapy","volume":"28","author":"Waheed","year":"2012","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2019.02.014_bib58","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/QAD.0b013e328331c83b","article-title":"Can the further clinical development of bevirimat be justified?","volume":"24","author":"Wainberg","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.02.014_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002997","article-title":"Structural and functional insights into the HIV-1 maturation inhibitor binding pocket","volume":"8","author":"Waki","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.02.014_bib60","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.apsb.2015.05.004","article-title":"Pharmacological intervention of HIV-1 maturation","volume":"5","author":"Wang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.antiviral.2019.02.014_bib61","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-017-01856-y","article-title":"Quenching protein dynamics interferes with HIV capsid maturation","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2019.02.014_bib62","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1128\/JVI.72.4.2846-2854.1998","article-title":"Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites","volume":"72","author":"Wiegers","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.014_bib63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1742-4690-1-15","article-title":"The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3\u2019,3\u2019-dimethylsuccinyl}-betulinic acid","volume":"1","author":"Zhou","year":"2004","journal-title":"Retrovirology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218307162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218307162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:40Z","timestamp":1759062520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218307162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":64,"alternative-id":["S0166354218307162"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.02.014","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insight into the mechanism of action of EP-39, a bevirimat derivative that inhibits HIV-1 maturation","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}